varicella zoster vaccine

✓ Approved

HK inno.N · 疫苗 · 疫苗

什么是 varicella zoster vaccine？

varicella zoster vaccine 是一种疫苗，由HK inno.N研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)。

药物档案

公司	HK inno.N
药物类别	疫苗, 大分子
给药途径	Injectable (Others)
状态	Approved

来源： ClinicalTrials.gov, HK inno.N

治疗适应症

varicella zoster vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域	疾病/病症	分期
Infections and infestations	Varicella zoster virus infection	✓ Approved

相关研究文献

PubMedGenomics, proteomics & bioinformatics2026-10-26

RNASTOP: A Deep Learning Framework for mRNA Chemical Stability Prediction and Optimization.

Lin Shenggeng S, Chen Junwei J, Sun Heqi H, Zhang Yufang Y et al.

Messenger RNA (mRNA) vaccines offer promising therapeutic potential for combating various diseases, yet their inherent chemical instability hampers long-term efficacy. Although several methods have been developed to predict mRNA degradation, they often suffer from limited accuracy and lack the capability for rational codon optimization. Here, we propose RNASTOP, a novel framework that integrates deep learning with heuristic search to simultaneously predict and optimize mRNA chemical stability. RNASTOP achieves a 13% improvement in accuracy over the top-performing model on the Stanford OpenVaccine competition dataset and demonstrates robust generalization in predicting full-length mRNA degradation. When applied to mRNA codon optimization, RNASTOP reduces the minimum free energy of the varicella-zoster virus vaccine sequence by 75.73% while maintaining high translation efficiency. Overall, RNASTOP serves as a powerful tool for predicting and optimizing mRNA chemical stability, accelerating the development of mRNA therapeutics. The source code of RNASTOP is available at https://github.com/xlab-BioAI/RNASTOP.

PMID 42928593

阅读全文 →

PubMedCureus2026-10-26

Atypical Presentation of Ramsay Hunt Syndrome in an Immunocompromised Patient: A Case Report.

Rash David J DJ, Mangeni Owori O

Ramsay Hunt syndrome (RHS), or herpes zoster oticus, is a rare neurological complication of varicella-zoster virus reactivation within the geniculate ganglion, leading to unilateral facial pain, facial paralysis, otalgia, sensorineural hearing loss, and a painful vesicular rash on the face or ear. Reactivation of the virus most often affects the vestibulocochlear (cranial nerve eight) and facial (cranial nerve seven) nerves in RHS. Early recognition of RHS is important as delays in treatment can lead to permanent facial paralysis, scarring, or irreversible sensorineural hearing loss. In this case, we examine an 84-year-old immunocompromised female patient whose diagnosis of RHS was delayed by multiple medical comorbidities and an atypical initial presentation.

PMID 42928848

阅读全文 →

PubMedCardiology in review2026-10-26

Herpes Zoster and Cardiovascular Disease: An Unexpected Association.

Patel Dhruv D, Kallash Mohammed M, Frishman William H WH

Herpes zoster (HZ), the reactivation of latent varicella zoster virus (VZV), is increasingly being recognized as more than a dermatologic and neurologic disease. In recent years, multiple meta-analyses have linked HZ infection to a clinically significant increase in the risk of stroke, myocardial infarction (MI), and other major adverse cardiovascular events, an effect that is most pronounced in the first days to weeks following the acute HZ infection, with a gradual decrease in risk over time. The proposed mechanism centers on a productive viral infection of arterial walls, a phenomenon described as VZV vasculopathy, with transmural inflammation, endothelial dysfunction, and thrombosis, all superimposed on the systemic inflammatory and prothrombotic state that accompanies the acute HZ infection. The evidence for an association between HZ infection and cardiovascular events has grown stronger with recent multiple large cohort studies demonstrating that patients who received HZ vaccination had a significantly lower rate of major adverse cardiovascular events, MI, stroke, heart failure, and arrhythmia. However, while these cohort studies have helped researchers identify the potential association of HZ vaccination and reduced cardiovascular risk, there remains a need for a randomized controlled trial to establish causality between these factors. Currently underway, a randomized controlled trial is directly evaluating whether HZ vaccination in a large population lowers the incidence of cardiovascular events, including stroke, MI, and cardiovascular death. Nevertheless, the 2026 American College of Cardiology guidelines now include a strong recommendation for HZ vaccination given the growing body of evidence regarding the association of HZ vaccination with cardiovascular events.

PMID 42928087

阅读全文 →

PubMedThe Medical journal of Australia2026-10-26

Short-Term Adverse Events Following Recombinant Zoster Vaccination in Older Adults in Australia: A Survey Study Comparing Dose 1 and Dose 2 and Influence of Dose Interval.

Dawes Lucy L, Nguyen Thuy T, Macartney Kristine K, Deng Lucy L

Self-reported adverse events following first and second recombinant zoster vaccination (RZV) doses in older adults (n = 41,069) collected through AusVaxSafety were analysed. Adverse event rates were higher following Dose 2 (54%; 95% CI, 53%-54%) than after Dose 1 (45%; 95% CI, 45%-46%), particularly with 3-6- and 7-9-month dose intervals, although medical review rates remained low (1.1%; 95% CI, 1.0%-1.2%), suggesting RZV is reactogenic but with no serious outcomes.

PMID 42928968

阅读全文 →

PubMedCancer discovery2026-10-26

First mRNA Cancer Vaccine Succeeds in Phase III Trial.

Adding the mRNA-based individualized neoantigen vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death by 42%, according to the results of the phase III INTerpath-0001 trial. The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.

PMID 42929716

阅读全文 →

PubMedAnimal health research reviews2026-10-26

Innovative vaccine strategies for sustainable control and eradication of peste des petits ruminants virus.

Bello Muhammad Bashir MB, Hameed Sodiq A SA, Abdullahi Adama Musa AM, Lawal Nafi'u N et al.

PMID 42929676

阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

varicella zoster vaccine

什么是 varicella zoster vaccine？

药物档案

治疗适应症

相关研究文献

RNASTOP: A Deep Learning Framework for mRNA Chemical Stability Prediction and Optimization.

Atypical Presentation of Ramsay Hunt Syndrome in an Immunocompromised Patient: A Case Report.

Herpes Zoster and Cardiovascular Disease: An Unexpected Association.

Short-Term Adverse Events Following Recombinant Zoster Vaccination in Older Adults in Australia: A Survey Study Comparing Dose 1 and Dose 2 and Influence of Dose Interval.

First mRNA Cancer Vaccine Succeeds in Phase III Trial.

Innovative vaccine strategies for sustainable control and eradication of peste des petits ruminants virus.

了解更多varicella zoster vaccine